Literature DB >> 20488818

Amelioration of nephropathy with apoA-1 mimetic peptide in apoE-deficient mice.

Nosratola D Vaziri1, Hyun Ju Kim, Hamid Moradi, Farbod Farmand, Kaveh Navab, Mohamad Navab, Susan Hama, Alan M Fogelman, Yasmir Quiroz, Bernardo Rodriguez-Iturbe.   

Abstract

BACKGROUND: There is mounting evidence that dyslipidaemia may contribute to development and progression of renal disease. For instance, hyperlipidaemia in apolipoprotein E-deficient (apoE(-/-)) mice is associated with glomerular inflammation, mesangial expansion and foam cell formation. ApoA-1 mimetic peptides are potent antioxidant and anti-inflammatory compounds which are highly effective in ameliorating atherosclerosis and inflammation in experimental animals. Given the central role of oxidative stress and inflammation in progression of renal disease, we hypothesized that apoA-1 mimetic peptide, D-4F, may attenuate renal lesions in apoE(-/-) mice.
METHODS: Twenty-five-month-old female apoE(-/-) mice were treated with D-4F (300 µg/mL in drinking water) or placebo for 6 weeks. Kidneys were harvested and examined for histological and biochemical characteristics.
RESULTS: Compared with the control mice, apoE(-/-) mice showed significant proteinuria, tubulo-interstitial inflammation, mesangial expansion, foam cell formation and up-regulation of oxidative [NAD(P)H oxidase subunits] and inflammatory [NF-κB, MCP-1, PAI-1 and COX-2] pathways. D-4F administration lowered proteinuria, improved renal histology and reversed up-regulation of inflammatory and oxidative pathways with only minimal changes in plasma lipid levels.
CONCLUSIONS: The apoE(-/-) mice develop proteinuria and glomerular and tubulo-interstitial injury which are associated with up-regulation of oxidative and inflammatory mediators in the kidney and are ameliorated by the administration of apoA-1 mimetic peptide. These observations point to the role of oxidative stress and inflammation in the pathogenesis of renal disease in hyperlipidaemic animals and perhaps humans.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20488818      PMCID: PMC2980997          DOI: 10.1093/ndt/gfq274

Source DB:  PubMed          Journal:  Nephrol Dial Transplant        ISSN: 0931-0509            Impact factor:   5.992


  47 in total

Review 1.  Lectin-like, oxidized low-density lipoprotein receptor-1 (LOX-1): a critical player in the development of atherosclerosis and related disorders.

Authors:  Jawahar L Mehta; Jiawei Chen; Paul L Hermonat; Francesco Romeo; Giuseppe Novelli
Journal:  Cardiovasc Res       Date:  2005-12-01       Impact factor: 10.787

Review 2.  Dyslipidemia of chronic renal failure: the nature, mechanisms, and potential consequences.

Authors:  N D Vaziri
Journal:  Am J Physiol Renal Physiol       Date:  2006-02

Review 3.  Causes of dysregulation of lipid metabolism in chronic renal failure.

Authors:  Nosratola D Vaziri
Journal:  Semin Dial       Date:  2009 Nov-Dec       Impact factor: 3.455

4.  Renal mass reduction results in accumulation of lipids and dysregulation of lipid regulatory proteins in the remnant kidney.

Authors:  Hyun Ju Kim; Hamid Moradi; Jun Yuan; Keith Norris; Nosratola D Vaziri
Journal:  Am J Physiol Renal Physiol       Date:  2009-04-08

5.  D-4F reduces EO6 immunoreactivity, SREBP-1c mRNA levels, and renal inflammation in LDL receptor-null mice fed a Western diet.

Authors:  Georgette M Buga; Joy S Frank; Giuliano A Mottino; Ashkan Hakhamian; Ajay Narasimha; Andrew D Watson; Babak Yekta; Mohamad Navab; Srinivasa T Reddy; G M Anantharamaiah; Alan M Fogelman
Journal:  J Lipid Res       Date:  2007-10-09       Impact factor: 5.922

6.  Treatment with an apolipoprotein A-1 mimetic peptide in combination with pravastatin inhibits collagen-induced arthritis.

Authors:  Christina Charles-Schoeman; Mona Lisa Banquerigo; Susan Hama; Mohamad Navab; Grace S Park; Brian J Van Lenten; Alan C Wagner; Alan M Fogelman; Ernest Brahn
Journal:  Clin Immunol       Date:  2008-03-12       Impact factor: 3.969

Review 7.  The effect of lipoproteins on the development and progression of renal disease.

Authors:  Lorien S Dalrymple; George A Kaysen
Journal:  Am J Nephrol       Date:  2008-04-24       Impact factor: 3.754

8.  In vitro stimulation of HDL anti-inflammatory activity and inhibition of LDL pro-inflammatory activity in the plasma of patients with end-stage renal disease by an apoA-1 mimetic peptide.

Authors:  Nosratola D Vaziri; Hamid Moradi; Madeleine V Pahl; Alan M Fogelman; Mohamad Navab
Journal:  Kidney Int       Date:  2009-05-27       Impact factor: 10.612

Review 9.  The effect of apolipoprotein mimetic peptides in inflammatory disorders other than atherosclerosis.

Authors:  Mohamad Navab; G M Anantharamaiah; Alan M Fogelman
Journal:  Trends Cardiovasc Med       Date:  2008-02       Impact factor: 6.677

Review 10.  Mouse models for atherosclerosis and pharmaceutical modifiers.

Authors:  Susanne Zadelaar; Robert Kleemann; Lars Verschuren; Jitske de Vries-Van der Weij; José van der Hoorn; Hans M Princen; Teake Kooistra
Journal:  Arterioscler Thromb Vasc Biol       Date:  2007-05-31       Impact factor: 8.311

View more
  9 in total

Review 1.  Recent progress in histochemistry and cell biology.

Authors:  Stefan Hübner; Athina Efthymiadis
Journal:  Histochem Cell Biol       Date:  2012-02-25       Impact factor: 4.304

2.  Role of apolipoprotein E in renal damage protection.

Authors:  F Bonomini; L F Rodella; M Moghadasian; C Lonati; R Coleman; R Rezzani
Journal:  Histochem Cell Biol       Date:  2011-05-15       Impact factor: 4.304

Review 3.  Systemic and renal lipids in kidney disease development and progression.

Authors:  Patricia Wahl; Gloria Michelle Ducasa; Alessia Fornoni
Journal:  Am J Physiol Renal Physiol       Date:  2015-12-23

4.  D-4F, an apoA-I mimetic peptide, inhibits proliferation and tumorigenicity of epithelial ovarian cancer cells by upregulating the antioxidant enzyme MnSOD.

Authors:  Ekambaram Ganapathy; Feng Su; David Meriwether; Asokan Devarajan; Victor Grijalva; Feng Gao; Arnab Chattopadhyay; G M Anantharamaiah; Mohamad Navab; Alan M Fogelman; Srinivasa T Reddy; Robin Farias-Eisner
Journal:  Int J Cancer       Date:  2011-05-26       Impact factor: 7.396

Review 5.  The Roles of Fatty Acids and Apolipoproteins in the Kidneys.

Authors:  Xiaoyue Pan
Journal:  Metabolites       Date:  2022-05-20

Review 6.  Kidney as modulator and target of "good/bad" HDL.

Authors:  Jianyong Zhong; Haichun Yang; Valentina Kon
Journal:  Pediatr Nephrol       Date:  2018-10-05       Impact factor: 3.714

7.  Hydroxypropyl-β-cyclodextrin protects from kidney disease in experimental Alport syndrome and focal segmental glomerulosclerosis.

Authors:  Alla Mitrofanova; Judith Molina; Javier Varona Santos; Johanna Guzman; Ximena A Morales; G Michelle Ducasa; Jonathan Bryn; Alexis Sloan; Ion Volosenco; Jin-Ju Kim; Mengyuan Ge; Shamroop K Mallela; Matthias Kretzler; Sean Eddy; Sebastian Martini; Patricia Wahl; Santiago Pastori; Armando J Mendez; George W Burke; Sandra Merscher; Alessia Fornoni
Journal:  Kidney Int       Date:  2018-10-06       Impact factor: 10.612

8.  ApoE deficiency promotes colon inflammation and enhances inflammatory potential oxidized-LDL and TNF-α in colon epithelial cells.

Authors:  Ali El-Bahrawy; Abdelmetalab Tarhuni; Hogyoung Kim; Venkat Subramaniam; Ilyes Benslimane; Zakaria Y Abd Elmageed; Samuel Okpechi; Mohamed Ghonim; Ramadan Hemeida; Amira Abo-Yousef; Gamal El-Sherbiny; Ihab Abdel-Raheem; Jong Kim; Amarjit S Naura; Hamid Boulares
Journal:  Biosci Rep       Date:  2016-08-18       Impact factor: 3.840

9.  Post-Stroke Administration of L-4F Promotes Neurovascular and White Matter Remodeling in Type-2 Diabetic Stroke Mice.

Authors:  Min Zhou; Rongwen Li; Poornima Venkat; Yu Qian; Michael Chopp; Alex Zacharek; Julie Landschoot-Ward; Brianna Powell; Quan Jiang; Xu Cui
Journal:  Front Neurol       Date:  2022-04-28       Impact factor: 4.003

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.